Mediolanum International Funds Ltd Acquires Shares of 260,877 Sanofi (NASDAQ:SNY)

Mediolanum International Funds Ltd acquired a new stake in Sanofi (NASDAQ:SNY - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 260,877 shares of the company's stock, valued at approximately $15,034,000.

A number of other large investors have also added to or reduced their stakes in SNY. Stablepoint Partners LLC lifted its holdings in Sanofi by 0.8% during the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company's stock worth $1,377,000 after buying an additional 189 shares during the period. Eagle Ridge Investment Management raised its position in shares of Sanofi by 3.8% during the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company's stock worth $321,000 after acquiring an additional 203 shares during the last quarter. TCTC Holdings LLC lifted its stake in shares of Sanofi by 28.0% in the first quarter. TCTC Holdings LLC now owns 960 shares of the company's stock worth $47,000 after acquiring an additional 210 shares during the period. HB Wealth Management LLC boosted its holdings in Sanofi by 3.7% in the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company's stock valued at $299,000 after acquiring an additional 221 shares during the last quarter. Finally, Insigneo Advisory Services LLC boosted its holdings in Sanofi by 3.3% in the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company's stock valued at $371,000 after acquiring an additional 228 shares during the last quarter. Institutional investors own 10.04% of the company's stock.

Sanofi Stock Up 4.4 %

Shares of NASDAQ:SNY traded up $2.29 during mid-day trading on Friday, hitting $54.34. 3,250,793 shares of the company traded hands, compared to its average volume of 2,033,069. The stock has a 50-day moving average price of $56.08 and a two-hundred day moving average price of $51.67. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The stock has a market cap of $137.89 billion, a P/E ratio of 29.53, a P/E/G ratio of 1.40 and a beta of 0.60. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business had revenue of $10.75 billion for the quarter, compared to analysts' expectations of $16.86 billion. During the same period in the previous year, the company earned $0.95 earnings per share. The firm's revenue for the quarter was up 7.8% compared to the same quarter last year. On average, equities research analysts forecast that Sanofi will post 4.23 earnings per share for the current year.

Analyst Ratings Changes

SNY has been the topic of a number of research analyst reports. Argus upped their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, July 26th. Citigroup raised Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, StockNews.com lowered Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Monday, October 14th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.